- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02912312
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
Shortening Adjuvant Photon Irradiation to Reduce Edema (SAPHIRE): A Randomized Trial of Hypofractionated Versus Conventionally Fractionated Regional Nodal Irradiation for Invasive Breast Cancer
Study Overview
Status
Conditions
Detailed Description
Primary Objective: To compare the risk of locoregional recurrence, defined as a cancer recurrence in the ipsilateral breast, chest wall, or regional lymph nodes (axillary levels I-III, supraclavicular, or internal mammary)
SECONDARY OBJECTIVES FOR BOTH COHORTS
- To compare the maximum standardized difference in arm volume between the affected arm and the unaffected arm within 24 months after completion of RNI between the two treatment arms.
- To compare maximal acute (within 6 weeks of treatment) and late (more than 6 weeks after treatment) skin and soft tissue toxicities using the NCI CTCAE v4.0 scale between patients assigned to short versus standard RNI.
- To compare patient-reported arm and shoulder function for the two treatment arms using the QuickDASH-9.
- To compare patient quality of life for the two treatment arms using EQ-5D-3L and PROMIS Fatigue SF 6a.
- To compare the peripheral blood cytokine profile at the end of radiation between patients assigned to short versus standard RNI.
- To evaluate the effect of the peripheral blood cytokine profile at the end of radiation on developing lymphedema. (optional blood draw for a subset of patients and not applicable for the participating Cancer Network Site patients, or Orlando Health)
- To evaluate the effect of homocysteine levels prior to radiation on developing lymphedema. (optional blood draw for a subset of patients and not applicable for the participating Cancer Network Site patients, or Orlando Health)
- To evaluate time to distant metastasis, disease-free survival and overall survival for patients assigned to short versus standard RNI.
- To evaluate the effect of lipid profiles prior to radiation on acute toxicity, patient reported outcomes, and the time to locoregional recurrence. (optional blood draw for a subset of patients and not applicable for the participating Cancer Network Site patients, or Orlando Health)
- To evaluate if DNA repair capacity contributes to the presence of acute radiation related toxicity and patient-reported quality of life decrements including fatigue and arm and shoulder symptoms. (optional blood draw for a subset of patients and not applicable for the participating Cancer Network Site patients, or Orlando Health)
- To evaluate changes in echocardiography global longitudinal strain measurements and cardiac serum biomarkers, based on measurements performed before and after RT, in patients assigned to short versus standard RNI. (optional procedure for a subset of patients and not applicable for the participating Cancer Network Site patients, or Orlando Health)
- In a separate cohort of 50 patients who will receive RNI before surgery, to collect information on number of patients developing lymphedema within 24 months of RNI on reconstructive complications, and on patient reported quality of life, in those assigned to short versus standard RNI. Participating Cancer Network Sites, or Orlando Health, are not participating in this cohort.
- To evaluate patient-reported financial burdens using the Economic Strain and Resilience in Cancer- Financial Well- Being instrument.
- To determine whether radiation therapy induces de novo detectable clonal hematopoiesis mutations or alters the genetic landscape of existing clonal hematopoiesis mutations (optional blood draw for a subset of patients and not applicable for the participating Cancer Network Site patients, or Orlando Health).
- To determine whether radiation therapy or chemotherapy among individuals with pre- and/or post-treatment clonal hematopoiesis mutations is associated with adverse treatment effects and worse oncologic outcomes (optional blood draw for a subset of patients and not applicable for the participating Cancer Network Site patients, or Orlando Health).
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo hypofractionated RNI in 15 fractions 5 consecutive days a week for 3 weeks.
ARM II: Patients undergo standard RNI in 25 fractions 5 consecutive days a week for 5 weeks.
In both arms, patients undergo additional boost dose of radiation therapy in 5 or 7 fractions on consecutive days following completion of RNI.
PATIENT EVALUATION: Patients participating in the trial will have their arm measured prior to radiation, during the final week of radiation and when they return for follow up visits. Patients will be checked for any arm swelling that may develop. Patients will also fill out questionnaires before treatment and when they return for follow up visits. Patients return 3 and 6 months after radiation, then every 6 months through two and a half years after radiation and then on a yearly basis until ten and a half years after finishing radiation. At some of the follow up visits, we measure arm volume and ask participants to complete questionnaires.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Karen Hoffman, MD
- Phone Number: 713-563-2331
- Email: khoffman1@mdanderson.org
Study Locations
-
-
Arizona
-
Gilbert, Arizona, United States, 85234
- Recruiting
- MD Anderson Cancer Center (Banner)
-
Contact:
- Mohamed Khan, MD
- Phone Number: 480-256-6444
- Email: mohamed.khan@bannerhealth.com
-
Principal Investigator:
- Mohamed Khan, MD
-
-
California
-
San Diego, California, United States, 92121
- Recruiting
- Scripps- MD Anderson Cancer
-
Contact:
- Ray Lin, MD
- Phone Number: 858-554-8788
- Email: lin.ray@scrippshealth.org
-
Principal Investigator:
- Ray Lin, MD
-
-
Colorado
-
Greeley, Colorado, United States, 80631
- Recruiting
- MD Anderson Cancer Center (Banner)- Northern Colorado
-
Contact:
- Supriya Jain, MD
- Phone Number: 970-810-3894
- Email: supriya.jain@bannerhealth.com
-
Principal Investigator:
- Supriya Jain, MD
-
-
Florida
-
Jacksonville, Florida, United States, 32207
- Recruiting
- Baptist - MD Anderson Cancer Center
-
Contact:
- Cynthia Anderson, MD
- Phone Number: 855-635-2667
- Email: cynthia.anderson@bmcjax.com
-
Principal Investigator:
- Cynthia Anderson, MD
-
Orlando, Florida, United States, 32806
- Recruiting
- Orlando Health Cancer Institute
-
Contact:
- Cameron Swanick, MD
- Phone Number: 321-841-8650
- Email: Cameron.Swanick@orlandohealth.com
-
Principal Investigator:
- Cameron Swanick, MD
-
-
Indiana
-
Indianapolis, Indiana, United States, 46219
- Recruiting
- Community MD Anderson Cancer Center East
-
Contact:
- Daniel Weed, M D
- Phone Number: 317-621-7771
- Email: dweed@ecommunity.com
-
Principal Investigator:
- Daniel Weed, M D
-
Indianapolis, Indiana, United States, 46227
- Recruiting
- Community MD Anderson Cancer Center South
-
Contact:
- Daniel Weed, M D
- Phone Number: 317-621-7771
- Email: dweed@ecommunity.com
-
Principal Investigator:
- Daniel Weed, M D
-
Indianapolis, Indiana, United States, 49625
- Recruiting
- Community MD Anderson Cancer Center North
-
Contact:
- Daniel Weed, M D
- Phone Number: 317-621-7771
- Email: dweed@ecommunity.com
-
Principal Investigator:
- Daniel Weed, M D
-
-
New Jersey
-
Camden, New Jersey, United States, 08103
- Recruiting
- Cooper Hospital University Medical Center
-
Contact:
- Stuti Ahlawat, MD
- Phone Number: 855-632-2667
- Email: ahlawat-stuti@CooperHealth.edu
-
Principal Investigator:
- Stuti Ahlawat, MD
-
-
Ohio
-
Columbus, Ohio, United States, 43215
- Recruiting
- Ohio Health
-
Contact:
- Virginia Davolitsis, MD
- Phone Number: 614-566-1250
- Email: virginia.diavolitsis@ohiohealth.com
-
Principal Investigator:
- Virginia Davolitsis, MD
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- M D Anderson Cancer Center
-
Contact:
- Karen E. Hoffman, MD
- Phone Number: 713-563-2331
-
Principal Investigator:
- Karen E. Hoffman, MD
-
San Antonio, Texas, United States, 78229
- Recruiting
- UT Health San Antonio - MD Anderson Cancer Center
-
Contact:
- Dalwadi Shraddha, M D
- Phone Number: 210-450-1000
- Email: dalwadis@uthscsc.edu
-
Principal Investigator:
- Dalwadi Shraddha, M D
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria, if receiving postoperative radiation therapy
- Radiation oncologist recommends radiation treatment to the supraclavicular and infraclavicular fossa (i.e. RNI).
- Pathologically-confirmed invasive breast cancer. If patients undergo upfront surgery, the pathologic stage must be T0-T3, N0-N2a or N3a. If patients receive neoadjuvant chemotherapy prior to surgery, the clinical stage must be T0-T3, N0-N2a or N3a. T4b disease is permitted if the patient undergoes breast conserving surgery.
- Treatment with mastectomy or segmental mastectomy and axillary evaluation (sentinel node evaluation, axillary sampling, or axillary lymph node dissection). If the patient has T0 disease, breast surgery is not required.
- Age 18 years or older.
- If enrolling on in the arm lymphedema assessment cohort, documentation of arm volume measurement by perometer prior to axillary surgery.
- If the patient has a history of a prior non-breast cancer, all treatment for this cancer must have been completed prior to study registration, and the patient must have no evidence of disease for this prior non-breast cancer.
- Patients must be enrolled on the trial within 24 weeks of the later of two dates: the final breast cancer surgical procedure or administration of the last cycle of cytotoxic chemotherapy. If after trial enrollment it is determined the patient requires additional cytotoxic chemotherapy or additional breast cancer surgery prior to radiation therapy the patient may stay on trial but the patient must start radiation therapy within 24 weeks of the final breast cancer surgical procedure or administration of the last cycle of cytotoxic chemotherapy.
Inclusion Criteria, if receiving preoperative radiation therapy
- Surgeon and radiation oncologist recommend preoperative radiation therapy
- Radiation oncologist recommends radiation treatment to the supraclavicular and infraclavicular fossa (i.e. RNI).
- Pathologically-confirmed invasive breast cancer. The clinical stage must be T0-T3, N0-N3b
- Planned treatment with mastectomy and axillary evaluation (sentinel node evaluation, axillary sampling, or axillary lymph node dissection).
- Planned breast reconstruction with autologous reconstruction.
- Age 18 years or older.
- If the patient has a history of a prior non-breast cancer, all treatment for this cancer must have been completed prior to study registration, and the patient must have no evidence of disease for this prior non-breast cancer.
Exclusion Criteria, if receiving postoperative radiation therapy
- Pathologic or clinical evidence for a stage T4 breast cancer. However, T4b disease is permitted if the patient undergoes breast conserving surgery.
- Pathologic or clinical evidence for a stage N2b, N3b, or N3c breast cancer (supraclavicular, or internal mammary lymph node involvement).
- Clinical or pathologic evidence for distant metastases.
- Current diagnosis of invasive breast cancer in the contralateral breast (ductal carcinoma in situ is permitted).
- Prior diagnosis of invasive breast cancer in the contralateral breast.
- If enrolling on in the arm lymphedema assessment cohort, current diagnosis of bilateral breast cancer.
- History of therapeutic irradiation to the breast, lower neck, mediastinum or other area in which there could potentially be overlap with the affected breast. Except those patients enrolled and treated on the PRECISE trial (MD Anderson 2017-0362).
- Patient is pregnant.
- Patients who are cognitively impaired. Subjects will undergo a brief physical exam including a brief exam to determine cognitive review.
Exclusion Criteria, if receiving preoperative radiation therapy
- Pathologic or clinical evidence for a stage T4 breast cancer.
- Pathologic or clinical evidence for a stage N3c breast cancer (supraclavicular lymph node involvement).
- Clinical or pathologic evidence for distant metastases.
- Current diagnosis of invasive breast cancer in the contralateral breast (ductal carcinoma in situ is permitted).
- Prior diagnosis of invasive breast cancer in the contralateral breast.
- History of therapeutic irradiation to the breast, lower neck, mediastinum or other area in which there could potentially be overlap with the affected breast. Except those patients enrolled and treated on the PRECISE trial (MD Anderson 2017-0362).
- Patient is pregnant.
- Patients who are cognitively impaired. Subjects will undergo a brief physical exam including a brief exam to determine cognitive review.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I: Hypofractionated Regional Nodal Irradiation (RNI)
Patients undergo hypofractionated RNI in 15 fractions 5 consecutive days a week for 3 weeks.
Patients also undergo additional boost dose of radiation therapy in 5 or 7 fractions on consecutive days following completion of RNI.
|
Correlative studies
Ancillary studies
Other Names:
Ancillary studies
Undergo hypofractionated RNI
Other Names:
|
Active Comparator: Arm II: Standard Regional Nodal Irradiation (RNI)
Patients undergo standard RNI in 25 fractions 5 consecutive days a week for 5 weeks.
Patients also undergo additional boost dose of radiation therapy in 5 or 7 fractions on consecutive days following completion of RNI.
|
Correlative studies
Ancillary studies
Other Names:
Ancillary studies
Undergo standard RNI
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lymphedema rate as assessed by perometry
Time Frame: Up to 24 months
|
Will compare between patients randomized to short versus standard regional nodal irradiation (RNI).
Will use a two-sided chi-squared test with a significance level of 0.05.
|
Up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Volume of affected and unaffected arm as assessed by perometry
Time Frame: Up to 126 months
|
The Shapiro-Wilk test will be used to objectively assess the normality of the data and these findings will be visually confirmed by inspecting normal probability quantile-quantile plots.
If the data are not normally distributed, a normalizing transformation before using t-test or a non-parametric method such as the Wilcoxon rank sum test to compare the standardized difference between the two arms at each time point may be used.
|
Up to 126 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Karen Hoffman, MD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016-0142 (Other Identifier: M D Anderson Cancer Center)
- NCI-2016-01941 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Invasive Breast Carcinoma
-
Sunnybrook Health Sciences CentreActive, not recruitingBreast Cancer | Invasive Lobular Breast Carcinoma | Invasive Ductal Breast CarcinomaCanada
-
H. Lee Moffitt Cancer Center and Research InstituteAmgenActive, not recruitingBreast Cancer | Invasive Breast Carcinoma | Invasive Ductal Breast Carcinoma | Ductal CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingEstrogen Receptor Positive | Ductal Breast Carcinoma In Situ | Grade 1 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Invasive Ductal and Lobular Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast CarcinomaUnited States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
University of ChicagoActive, not recruitingLung Metastases | Liver Metastases | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer | Invasive Lobular Breast Carcinoma | Central Nervous System Metastases | Tumors Metastatic to Brain | Lobular Breast Carcinoma in Situ | Invasive Ductal Breast Carcinoma | Medullary Ductal Breast Carcinoma... and other conditionsUnited States
-
Fondazione MichelangeloCompletedInvasive Ductal Breast CarcinomaSpain, Ireland, Italy, Taiwan, Germany, Austria, Russian Federation
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | Invasive Ductal Breast Carcinoma | Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate | Mucinous Ductal Breast Carcinoma | Papillary Ductal Breast... and other conditionsUnited States
-
Institut du Cancer de Montpellier - Val d'AurelleActive, not recruitingInvasive Breast Cancer | Breast-conserving SurgeryFrance
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Invasive Lobular Breast Carcinoma | Invasive Ductal Breast CarcinomaUnited States, Puerto Rico
-
St. Joseph Hospital of OrangeCompletedStage 0 Breast Carcinoma | Stage I Breast Carcinoma | Stage II Breast Carcinoma | Invasive Ductal and Invasive Lobular Breast CarcinomaUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States